CLEVELAND – The Cleveland Clinic will lead a huge international study to learn whether painkillers taken by millions of Americans for arthritis are safe for those at risk of heart problems.
With an unusual mix of industry, academic researchers and government oversight, the study also aims to restore public confidence in the wake of the Vioxx debacle.
“There’s only one way, through good science,” said Dr. Steven Nissen, the Cleveland cardiologist who will lead the study. “We know the burden is upon us to do this right.”
Drug safety and the credibility of research have been concerns in recent months since Vioxx and Bextra were pulled from the market because of evidence they can raise the risk of a heart attack or stroke. That left Pfizer Inc.’s Celebrex as the only available cox-2 inhibitor, drugs that became blockbusters because they were gentler on the stomach than older pain relievers.
Many people who switched to over-the-counter pain relievers called nonsteroidal anti-inflammatory drugs, or NSAIDs, then had a new worry when the Food and Drug Administration ordered stronger warning labels earlier this year.
The new study will test Celebrex and two types of NSAIDs – ibuprofen (sold as Motrin, Advil and other brands) and naproxen (Naprosyn, Aleve).
About 20,000 people throughout the United States, Eastern Europe, Canada, Australia and South America will be randomly assigned to get one of the three; neither they nor their doctors will know which. They’ll also be given a drug to prevent stomach irritation so each pain reliever’s true effectiveness can be assessed. Drugs and follow-up medical monitoring will be free.
Pfizer will fund the study, expected to cost more than $100 million, but independent researchers will collect and control the results and have offered to make all of them public, not just bottom-line conclusions. No top researchers can have financial ties to any pain drug manufacturers.
Results are expected in about four years but could come sooner if one drug proves significantly more dangerous that the others.
Talk to us
> Give us your news tips.
> Send us a letter to the editor.
> More Herald contact information.
